Health Condition 1: E119- Type 2 diabetes mellitus without complications
Conditions
Interventions
None listed
Sponsors
Mankind Pharma Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male or female patients, age � 18 to � 85 years. 2. Uncontrolled Type 2 diabetes with a haemoglobin A1c (HbA1c) �7.0 percent. 3. eGFR (MDRD) at screening > 60 mL/min/1.73m2 4. Patients who are prescribed Teneligliptin and Metformin combination therapy as part of routine clinical practice.
Exclusion criteria
Exclusion criteria: 1. Female patients who are pregnant or breast feeding 2. Patients with known liver or kidney dysfunction 3. Patients who are suspected of or known to have an intolerance to Teneligliptin or Metformin. 4. Presence of any other clinically significant disease or laboratory findings that in the Investigators opinion may affect the study outcomes or continued participation of patient in the study. 5. Participation in another study concurrently or within 4 weeks prior to the Screening Visit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate the Change in eGFR as compared to baseline at 3 months and 6 monthsTimepoint: Evaluate the Change in eGFR as compared to baseline at 3 months and 6 months | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Change in HbA1c as compared to baseline at 3 months and 6 months. 2. Change in Fasting Plasma Glucose (FPG) and Postprandial Plasma Glucose (PPG) as compared to baseline at 3 months and 6 months. 3. Number of patients with target HbA1c level of 7 percent at 3 months and 6 months. Timepoint: Baseline, 3 months and 6 months. | — |
Countries
India
Contacts
Public ContactRitesh Khandelwal
K.G.N. Diabetes and Endocrinology Centre
Outcome results
None listed